- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.
Clinical results from investigator-sponsored studies will be reported, including an ongoing study evaluating the combination of lapatinib and nab®-paclitaxel for first-line treatment of HER2+ breast cancer. Additional presentations will highlight analyses of cost of care in metastatic breast cancer patients, as well as the correlation between specific genotypes and treatment response rates.
ABRAXANE is currently approved in the second-line treatment of metastatic breast cancer and Abraxis continues to study the potential of ABRAXANE in areas of high unmet patient needs.
Metastatic breast cancer, also known as stage IV, refers to cancer that has spread to distant organs. In the majority of metastatic breast cancer patients, the metastasis is diagnosed after a cancer has already been treated. However, in about six to ten percent of all breast cancer patients, the cancer has spread to distant organs at the time of the first diagnosis. In the United States, there are 155,000 women and men living with metastatic breast cancer(i).
Results to be presented at the meeting include:
-A Taxane total cost of care analysis: Results of private payor claims data in metastatic breast cancer (Abstract #1076) Poster Presentation 1076; Thursday, December 10, 2009, 5:30 p.m. - 7:30 p.m.; Exhibit Halls A-B
-Pilot neoadjuvant trial with combination of lapatinib and nab®-paclitaxel in HER2+ breast cancer (Abstract #1091) Poster Presentation 1091; Thursday, December 10, 2009, 5:30 p.m.-7:30 p.m.; Exhibit Halls A-B
-The basal-like, luminal-like, and HER2-like genotype and the 70-gene signatures predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab®-paclitaxel and carboplatin +/- trastuzumab (trast) as part of (NCT) in patients (pts) with stage II-III breast cancer [including inflammatory breast cancer (BC)]. (Abstract #2026) Poster Presentation 2026; Friday, December 11, 2009, 7:00 a.m. - 9:00 a.m., Exhibit Halls A-B
iMetastatic Breast Cancer Network, www.mbcnetwork.org/page.aspx?nm=mainpage Accessed November 2009.
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab®platform. The first FDA approved product to use this nab®platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab®platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.
ABRAXANE® is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience's proprietary nab® technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin, a naturally occurring human protein. By wrapping the albumin around the active drug, ABRAXANE can be administered to patients at higher doses, delivering higher concentrations of paclitaxel to the tumor site than solvent-based paclitaxel. ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: expanded applications for metastatic breast, non-small cell lung, malignant melanoma, pancreatic and gastric.
The U.S. Food and Drug Administration approved ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The U.S. Food and Drug Administration granted orphan-drug designation for ABRAXANE for the treatment of pancreatic cancer in September 2009 and stage IIb to IV melanoma in October 2009. For the full prescribing information for ABRAXANE please visit www.abraxane.com.
For more information, please click here
Investors and Media Inquiries
Abraxis BioScience, Inc.
Copyright © Abraxis BioScienceIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Kalam: versatility personified August 1st, 2015
Gold-diamond nanodevice for hyperlocalised cancer therapy: Gold nanorods can be used as remote controlled nanoheaters delivering the right amount of thermal treatment to cancer cells, thanks to diamond nanocrystals used as temperature sensors August 1st, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
Self-assembling, biomimetic membranes may aid water filtration August 1st, 2015
March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015
Nanometrics Announces Upcoming Investor Events July 28th, 2015
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015
Spintronics: Molecules stabilizing magnetism: Organic molecules fixing the magnetic orientation of a cobalt surface/ building block for a compact and low-cost storage technology/ publication in Nature Materials July 25th, 2015